Reference entry · Acylated GLP-1 receptor agonist
Liraglutide
Also known as: GLP-1 receptor agonist · Victoza/Saxenda (approved drug names)
- Class
- Acylated GLP-1 receptor agonist
- Primary targets (literature)
- GLP-1 receptor
- Regulatory context
- FDA-approved drug (branded products exist). Catalog liraglutide for laboratory use is not those approved products without explicit documentation.
Overview
Liraglutide is an earlier-generation acylated GLP-1 receptor agonist with extensive published trial literature as an approved drug. Catalog research peptide labeled liraglutide is separate RUO material requiring full acylation verification.
Mechanism in research literature
GLP-1 receptor activation influences glucose-dependent insulin secretion, glucagon suppression, gastric emptying, and central satiety pathways — the foundational incretin pharmacology class.
Common research focus areas
- LEADER and SCALE trial program literature
- Daily-dosing acylation pharmacology vs. semaglutide
- Catalog vs. pharmaceutical product distinction
- Mass-spec confirmation of palmitoyl side chain
Full literature roundup
Read the cited research summary
An acylated GLP-1 receptor agonist with extensive published trial literature. What mechanisms and evidence tiers mean for research-grade material.
Liraglutide research roundup · 8 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.